Our lab aims to reverse glial scar back to normal neural tissue by gene delivery and/or chemical treatment.
Recently, We have discovered a cocktail of small molecules that can reprogram human brain astroglial cells into neuron-like cells after eight-to-ten days of chemical treatment.The small molecule induced neurons could survive for more than five months in cell culture, where they formed functional synaptic networks. When injected in the brains of living mice,the reprogrammed human neurons were integrated into the neural circuits and survived there for at least one month.
The new technology opens the door to the future development of drugs that patients with brain disorders could take as pills to regenerate neurons!
Learn more: Chemically transform human glial cells into neurons for brain repair
The Latest on: Gene delivery
[google_news title=”” keyword=”gene delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene delivery
- ASGT 2024: Gene Therapy Delivery and Development Dominates Opening Workshopon May 7, 2024 at 3:15 pm
In one of the opening workshops at ASGCT 2024, topics around delivery methods for gene therapies and approaches to expand the gene editing toolbox dominated the discussion. The quality of the ...
- Opinion: A CRISPR breakthrough? The gene therapy has been approved to treat sickle-cell diseaseon May 7, 2024 at 3:05 pm
A new gene therapy, utilizing the gene-editing tool known as CRISPR to treat sickle-cell disease, has received approval in the U.K., the U.S., and the EU. This milestone marks a potential breakthrough ...
- Nanoparticle researchers develop microfluidic platform for better delivery of gene therapy for lung diseaseon May 7, 2024 at 7:14 am
Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.
- Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meetingon May 7, 2024 at 5:00 am
Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced multiple poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, ...
- ANJARIUM BIOSCIENCES PRESENTS DATA DEMONSTRATING NOVEL SYNTHETIC DNA APPLICATIONS FOR CELL AND GENE THERAPIES at 27th ANNUAL ASGCT MEETINGon May 7, 2024 at 4:00 am
Anjarium Biosciences, a cell and gene therapy tools and technology company enabling researchers and manufacturers to accelerate the discovery and delivery cycle of new and evolving genetic medicines, ...
- Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conferenceon May 7, 2024 at 3:41 am
These data are the first demonstration of therapeutic payload delivery with an ANV vector and represent an initial investigation into the potential use of this novel platform to treat eye diseases ...
- Dark-field X-ray imaging reveals potential of nanoparticle-delivered gene therapyon May 7, 2024 at 1:30 am
The use of magnetically guided nanoparticles as targeted delivery vehicles could one day lead to a treatment for cystic fibrosis ...
- Experimental gene therapy restores some vision in patients with inherited blindnesson May 6, 2024 at 7:32 am
For her entire life, college student Olivia Cook had only a small degree of central vision. It was as if she was watching the world through a straw hole, and in dimly lit places, she could not make ...
- ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sectoron May 5, 2024 at 9:06 pm
Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect to learn about in Baltimore this week.
via Bing News
